Fig 1.
Abbreviations: DEMO, demographic and administrative information; INDI, indications for use/diagnosis; DRUG, drug details; REAC, coded adverse events.
Table 1.
Demographic information on malignancy risks with DPP4 inhibitors.
Fig 2.
Malignancy adverse event risks of different DPP4 inhibitors at the SMQ level.
Note: ROR025 and IC025 represent the lower limits of the 95% confidence intervals of ROR and IC, respectively. Signals were defined when both ROR025 > 1, and IC025 > 0. The * represents IC025 < 0.
Fig 3.
Malignancy adverse event risks of different DPP4 inhibitors at the PT level.
Note: ROR025 and IC025 represent the lower limits of the 95% confidence intervals of ROR and IC, respectively. Signals were defined when both ROR025 > 1, and IC025 > 0. The * represents IC025 < 0.
Table 2.
Sensitivity analysis of malignancy adverse events associated with DPP4 inhibitors.
Fig 4.
Time to onset of malignancy adverse events.
Abbreviations: IQR, interquartile range; N, Number of reported cases.